Amplia Therapeutics Limited's (ASX:ATX) Dr John Lambert speaks to Proactive's Andrew Scott following the news they've begun dosing the first volunteers in its Phase 1 clinical trial of AMP945. The molecule's being developed for difficult-to-treat cancers and fibrotic diseases. Amplia expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021.
viewAmplia Therapeutics Ltd
(
ASX:ATX
)
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Quick facts: Amplia Therapeutics Ltd
Follow
ASX:ATX
Price: 0.21 AUD
Market Cap: $26.21 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Amplia Therapeutics shifts from pre-clinical to drug development with...
Most read
Mining
Lake Resources halted pending news on material agreement with technology partner
5 days, 8 hours ago
